Open Access

Accumulation of connective tissue growth factor+ cells during the early phase of rat traumatic brain injury

  • Yuqi Liu1,
  • Zongwei Liu1,
  • Xiaoming Li1,
  • Bangwei Luo1,
  • Jian Xiong1,
  • Woting Gan1,
  • Man Jiang1,
  • Zhiyuan Zhang2,
  • Hermann J Schluesener2 and
  • Zhiren Zhang1Email author
Diagnostic Pathology20149:141

DOI: 10.1186/1746-1596-9-141

Received: 15 March 2014

Accepted: 1 July 2014

Published: 10 July 2014



Glial scar formation is a common histopathological feature of traumatic brain injury (TBI). Astrogliosis and expression of transforming growth factor beta (TGF-β) are key components of scar formation and blood-brain barrier modulation. Connective tissue growth factor (CTGF) is considered a cytokine mediating the effects of TGF-β.


Here, we studied the CTGF expression in an open-skull weight-drop-induced TBI, with a focus on the early phase, most amenable to therapy.


In normal rat brains of our study, CTGF+ cells were rarely observed. Significant parenchymal accumulation of CTGF+ non-neuron cells was observed 72 h post-TBI and increased continuously during the investigating time. We also observed that the accumulated CTGF+ non-neuron cells were mainly distributed in the perilesional areas and showed activated astrocyte phenotypes with typical stellate morphologic characteristics.


Our observations demonstrated the time-dependent and lesion-associated accumulation of cellular CTGF expression in TBI, suggesting a pathological role of CTGF in TBI.

Virtual Slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​3963462091241165​


Connective tissue growth factor Astrocytes Weight-drop model Traumatic brain injury


Glial scar formation is a common histopathological feature of traumatic brain injury (TBI). It persists for long periods and acts as barrier not only to axon regeneration but also to inflammatory cells in a manner that protects healthy tissue from nearby areas of intense inflammation [1]. Reactive astrocytosis is the key contributes to glial scar formation [2]. Induced by stimuli from lesions, astrocytes enter into the injured zone, are activated, and play a major role in the response to TBI. In central nervous system (CNS) injuries, activated astrocytes secrete many cytokines, among which transforming growth factor (TGF)-β is regarded as one of the most potent cytokines, it can be selectively upregulated in astrocytes and contribute to scar formation after injury through inducing secretion of another “downstream mediator”, the cytokine connective tissue growth factor (CTGF) [3, 4].

CTGF is a secreted peptide encoded by an immediate early growth responsive gene that has been shown to be a downstream mediator of TGF-β1 action, induces mitogenesis, chemotaxis, and cell matrix induction of fibroblasts [5]. Due to these properties, CTGF plays important roles in the regulation of scar formation, wound healing, cell migration, proliferation and extracellular matrix [4, 6]. A series of studies has also demonstrated that CTGF over-expression correlates with many fibrotic and inflammation-associated diseases, such as fibrotic skin disease, atherosclerosis and inflammatory bowel disease [79].

Upregulation of CTGF has been observed in a variety of nervous system-related disorders. In Alzheimer’s disease, CTGF was observed to overexpress in perivascular astrocytes and in astrocytes associated with plaques, indicating the role for CTGF in the process of chronic neurodegeneration [10]. In amyotrophic lateral sclerosis, CTGF was dramatically increased in reactive astrocytes of the ventral horn, supporting a role for CTGF in the molecular mechanisms underlying astrogliosis [11]. Although the expression of CTGF has been reported in human TBI, mice spinal cord injury, and rat kainic acid-induced brain injury, altered CTGF expression following TBI models are not completely clear. Therefore, in the current study, we have investigated the spatiotemporal expression of CTGF following an open-skull weight-drop-induced TBI in rat brains.


Animal experiments and tissue library

Brain libraries of normal and TBI rats have been described previously [12]. In brief, male Lewis rats (8–9 weeks of age, 350–400 g; Elevage Janvier, Le Genest-St-Isle, France) were housed under equal daily periods of light and dark and with free access to food and water. All procedures were performed in accordance with the published International Health Guidelines under a protocol approved by the Administration District Official Committee. The number of rats used and their suffering were minimized. TBI was induced in anesthetized rats using an open-skull weight-drop contusion model. Rats were grouped randomly, anesthetized with Ketamine (120 mg/kg)/Rompun (8 mg/kg), and subjected to craniotomy, in which a circular region of the skull (3.0 mm diameter, centered 2.3 mm caudal and 2.3 mm lateral to bregma) was removed over the right somatosensory cortex. A weight-drop device was placed over the dura and adjusted to stop an impact transducer (foot plate) at a depth of 2.5 mm below the dura. Then, a 20 g weight was dropped from 15 cm above the dura, through a guiding tube onto the foot plate. Body temperature was maintained using an overhead heating lamp during surgery. After injury, the scalp was closed tightly. Rats with TBI survived without further treatment and were euthanized at different time points (6, 12, 18, 24, 48, 72, and 96 h; 3–5 rats/time point).

For euthanasia, rats (26 TBI rats, five normal control rats) were deeply anesthetized with Ketamine (120 mg/kg)/Rompun (8 mg/kg) and perfused intracardially with 4°C 4% paraformaldehyde in PBS. Brains were quickly removed and postfixed in 4% paraformaldehyde overnight at 4°C. Fixed rat whole brains were placed in rodent brain matrices (coronal) and were sliced to obtain the cortical coronal blocks containing the contusion regions. These cortical coronal blocks were embedded in paraffin, serially sectioned (3 μm) through the center of the traumatized area, and mounted on silan-covered slides. The contused areas were numbered and during the subsequent immunostaining, the same antibody was applied to sections with the same number.


After dewaxing, brain sections were boiled (in an 850 W microwave oven) for 15 min in citrate buffer (2.1 g citric acid monohydrate/l, pH = 6) (Carl Roth, Karlsruhe, Germany). Endogenous peroxidase was inhibited by 1% H2O2 in pure methanol (Merck, Darmstadt, Germany) for 15 min. Sections were incubated with 10% normal pig serum (Biochrom, Berlin, Germany) to block nonspecific binding of immunoglobulins and then with the polyclonal antibody CTGF (1:100, BMA; USbio, Swampscott, Massachusetts, USA) overnight at 4°C. Antibody binding to tissue sections was visualized with a biotinylated rabbit anti-mouse IgG F(ab)2 antibody fragment (1 : 400; Dako, Hamburg, Germany). Subsequently, sections were incubated with a horseradish peroxidase-conjugated streptavidin complex for 30 min (1: 100; Dako), followed by development with diaminobenzidine substrate (Fluka, Neu-Ulm, Germany). Finally, sections were counterstained with Mayer’s hemalaun. As negative controls, the primary antibodies were excluded.

Data acquisition and statistical analysis

After immunostaining, the brain sections of each time point were examined by light microscopy. The numbers of CTGF+ non-neuron cells were counted in eight nonoverlapping high-power fields (×400 magnification) for each section. The high-power fields were selected to have a maximum of positive cells. In each field studied, only positive cells with the nucleus at the focal plane were counted. Results were presented as arithmetic means of CTGF+ non-neuron cells per high-power fields and SEM.

Statistical analysis was carried out using one-way analysis of variance, followed by Dunnett’s multiple comparison tests or a nonparametric t-test (GraphPad Prism 4.0 Software, San Diego, USA). For all statistical analyses, significance levels were set at P value less than 0.05.


A reproducible local lesion is formed on open-skull weight-drop injury in the ipsilateral cortex. The development of the lesion following TBI was analyzed using H&E staining has been described previously [13]. In brief, selective neuronal loss and necrotic loci condensed at the edge of impact site were observed 12 h postinjury (p.i.). Significant leukocyte infiltration and hemorrhage were already observed on day 1. At day 4 post-TBI, a lesioned cavity together with its surrounding perilesional tissue loss was formed under the impact areas. At the lesional areas, most tissue was lost, no neurons remained, and leukocyte infiltration together with hemorrhage appeared. In the perilesional areas, selective neuron loss with leukocyte infiltration was observed. In the subcortical white matter, no morphological changes were observed.

The expression of CTGF post-TBI was studied using immunohistochemistry. In normal adult rat brain, CTGF immunoreactivity was rarely observed in the cortex and meningeal (0.20 ± 0.194 per high-power field, Figures 1A and 2), only a few CTGF immunoreactivity was demonstrated in small vessels (Figure 1A, box indicated). Furthermore, almost all ependymal cells showed CTGF+ (Figure 1B). After TBI, no visible change in CTGF immunoreactivity was detected in the contralateral hemisphere (data not shown). In the injured (ipsilateral) sides, we found that CTGF expression in neurons did not change significantly, but the accumulation of non-neuron CTGF+ cells was observed in the lesion and perilesional areas (Figure 1C, arrows indicated). We then quantified the non-neuron CTGF+ cells in lesional areas. CTGF+ neurons were not counted. After TBI, a slight increase in CTGF+ non-neuron cells was observed confined to the lesion as early as 6 h p.i. (0.50 ± 0.497 per high-power field, P > 0.05, Figures 1D and 2). The accumulation of CTGF+ non-neuron cells increased over time (Figures 1E, F and 2). The accumulation of CTGF+ non-neuron cells became significant at 72-h post-TBI (17.40 ± 1.503 per high-power field, P < 0.01, Figures 1G and 2) and reached the maximum at 96-h post-TBI (74.20 ± 7.248, P < 0.01, Figures 1H and 2) during our observed time period.
Figure 1

Accumulation of connective tissue growth factor + (CTGF + ) non-neuron cells in traumatic brain injury. A: In normal brains, CTGF immunoreactivity was occasionally observed in the brain tissue. The boxed area indicates CTGF immunoreactivity in small vessels. B: Almost all ependymal cells showed CTGF+. C-H: The accumulation of CTGF+ cells in the lesioned regions at 18 h (C), 6 h (D), 24 h (E), 48 h (F), 72 h (G) and 96 h (H). Arrows indicate the accumulation of CTGF+ non-neuron cells with astrocytes phenotype in the cortex and meningeal (C). CTGF immunoreactivity was also detected in endothelial cells (F). A significant increase in CTGF+ non-neuron cells was observed confined to the lesion at 72 h postinjury (G). The boxed area indicates the localization of CTGF+ non-neuron cells that were mainly identified as astrocytes with typical stellate morphologic characteristics or belt-shaped, grouped pattern. The accumulation of CTGF+ non-neuron cells reached the maximum at 96-h postinjury (H). Scale bars are 50 μm.
Figure 2

The time course of parenchymal connective tissue growth factor + (CTGF + ) non-neuron cell accumulation in traumatic brain injury. The numbers of CTGF+ cells of every rat brain were counted in eight high-power fields. We only counted positive cells with the nucleus at the focal plane. Results are presented as arithmetic means of positive cells per high-power field and SEM. Statistical analysis was carried out using one-way analysis of variance, followed by Dunnett’s multiple comparison test (GraphPad Prism 4.0 Software). **P < 0.01 compared with the normal control.

The accumulation of CTGF+ non-neuron cells was mainly in perilesional areas but not in remote areas of the ipsilateral and contralateral hemispheres. At the lesioned site, most of the CTGF+ non-neuron cells showed activated astrocytes phenotypes with typical stellate morphologic characteristics or belt-shaped, grouped pattern (Figure 1G, box indicated). CTGF immunoreactivity was also detected in endothelial cells (Figure 1F, arrows indicated), but no significant differences were observed between injured and control brains.


Here we analyzed the accumulation of CTGF+ non-neuron cells in rat brain of weight-drop contusion following TBI. Significant CTGF+ non-neuron cell accumulation was detected 72-h p.i. and increased markedly. The CTGF+ non-neuron cells mainly detected in perilesioned areas where CTGF accumulation various in different time course. Furthermore, most CTGF+ non-neuron cells showed activated astrocyte phenotypes with typical stellate morphologic characteristics.

Nowadays, increasingly studies are focusing on the recovery stage after neural tissue injury [14], through which more pro-recovering molecules are discovered [15]. CTGF is investigated as a secreted cell matrix-inducing peptide involved in both tissue regeneration mechanisms [3]. In normal rat brains, CTGF expression can be found in glia-like cells, neurons, endothelial cells and ependymal cells [6]. In the CNS, increased expression of CTGF was induced under certain pathological conditions, such as spinal cord injury and cerebral infarction [6, 16]. It was demonstrated that in kainic acid-induced brain injury, significantly increasing of CTGF mRNA expression was limited in the ipsilateral hippocampus, no CTGF protein expression was observed in non-lesioned hippocampus [16]. However, in the current investigation, using an open-skull weight-drop injury, which is considered to cause less learning and memory deficits and produce less degenerating neurons compared with kainic acid-induced brain injury model [17], the accumulation of non-neuron CTGF+ cells was not only in the direct vicinity of the lesion core, but also in cells with astrocyte phenotypes which located on non-lesioned areas.

Accumulation of CTGF+ astrocytes is a well-established response to traumatic brain injury, which contributes to wound healing and glial scar formation, and is beneficial for TBI recovery [16]. Reactive CTGF+ cells with astrocyte phenotypes accumulated rapidly after TBI. In 6-h p.i., CTGF+ cells with astrocyte phenotypes accumulated in the direct vicinity of the lesion core in the cortex, while as early as 6 h p.i., CTGF+ cells with parenchymal astrocyte phenotypes was detected in the non-lesioned areas. These results suggest a participation of CTGF in the pathological features within the astrocytic compartment. Glial/collagen scarring is composed of dense packed reactive astrocytes and matrix protein deposition sealed by formation of a new basal lamina. Hence, the restricted expression and accumulation of CTGF in TBI adds convincing evidence for the participation of CTGF in the early astrocytic CNS injury response as a key molecule contributing to TBI recovery.


We have found an early accumulation of CTGF+ cells in open-skull weight-drop-induced TBI. Our study suggests that CTGF expression might define a subtype of activated astrocytes with a specific role in the tissue-repair processes following TBI.



Connective tissue growth factor


Traumatic brain injury


Central nervous system


Transforming growth factor.



This investigation was supported by the National Science and Technology Major Projects of New Drugs (2012ZX09103301-035) and the SRF for ROCS, SEM.

Authors’ Affiliations

Institute of Immunology, Third Military Medical University
Institute of Brain Research, University of Tuebingen


  1. Sofroniew MV: Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32 (12): 638-647. 10.1016/j.tins.2009.08.002.PubMedPubMed CentralView Article
  2. Norenberg MD: Astrocyte responses to CNS injury. J Neuropathol Exp Neurol. 1994, 53 (3): 213-220. 10.1097/00005072-199405000-00001.PubMedView Article
  3. Grotendorst GR: Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997, 8 (3): 171-179. 10.1016/S1359-6101(97)00010-5.PubMedView Article
  4. Logan A, Berry M, Gonzalez AM, Frautschy SA, Sporn MB, Baird A: Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. Eur J Neurosci. 1994, 6 (3): 355-363. 10.1111/j.1460-9568.1994.tb00278.x.PubMedView Article
  5. Steffen CL, Ball-Mirth DK, Harding PA, Bhattacharyya N, Pillai S, Brigstock DR: Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by fibroblast cells in vitro. Growth Factors. 1998, 15 (3): 199-213. 10.3109/08977199809002117.PubMedView Article
  6. Schwab JM, Postler E, Nguyen TD, Mittelbronn M, Meyermann R, Schluesener HJ: Connective tissue growth factor is expressed by a subset of reactive astrocytes in human cerebral infarction. Neuropathol Appl Neurobiol. 2000, 26 (5): 434-440. 10.1046/j.1365-2990.2000.00271.x.PubMedView Article
  7. Dammeier J, Brauchle M, Falk W, Grotendorst GR, Werner S: Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease?. Int J Biochem Cell Biol. 1998, 30 (8): 909-922. 10.1016/S1357-2725(98)00046-6.PubMedView Article
  8. Oemar BS, Werner A, Garnier JM, Do DD, Godoy N, Nauck M, Marz W, Rupp J, Pech M, Luscher TF: Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation. 1997, 95 (4): 831-839. 10.1161/01.CIR.95.4.831.PubMedView Article
  9. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, Takehara K: Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol. 1995, 105 (2): 280-284. 10.1111/1523-1747.ep12318465.PubMedView Article
  10. Ueberham U, Ueberham E, Gruschka H, Arendt T: Connective tissue growth factor in Alzheimer’s disease. Neuroscience. 2003, 116 (1): 1-6. 10.1016/S0306-4522(02)00670-X.PubMedView Article
  11. Spliet WG, Aronica E, Ramkema M, Aten J, Troost D: Increased expression of connective tissue growth factor in amyotrophic lateral sclerosis human spinal cord. Acta Neuropathol. 2003, 106 (5): 449-457. 10.1007/s00401-003-0741-y.PubMedView Article
  12. Liu Y, Zhang Z, Luo B, Schluesener HJ, Zhang Z: Lesional accumulation of heme oxygenase-1+ microglia/macrophages in rat traumatic brain injury. Neuroreport. 2013, 24 (6): 281-286. 10.1097/WNR.0b013e32835f2810.PubMedView Article
  13. Zhang Z, Artelt M, Burnet M, Trautmann K, Schluesener HJ: Early infiltration of CD8+ macrophages/microglia to lesions of rat traumatic brain injury. Neuroscience. 2006, 141 (2): 637-644. 10.1016/j.neuroscience.2006.04.027.PubMedView Article
  14. Rongchao S, Shudong Y, Zhiyi Z: Pathological and immunohistochemical study of lethal primary brain stem injuries. Diagn Pathol. 2012, 7: 54-10.1186/1746-1596-7-54.PubMedPubMed CentralView Article
  15. Hobbenaghi R, Javanbakht J, Hosseini E, Mohammadi S, Rajabian M, Moayeri P, Aghamohammad HM: Neuropathological and neuroprotective features of vitamin B12 on the dorsal spinal ganglion of rats after the experimental crush of sciatic nerve: an experimental study. Diagn Pathol. 2013, 8: 123-10.1186/1746-1596-8-123.PubMedPubMed CentralView Article
  16. Hertel M, Tretter Y, Alzheimer C, Werner S: Connective tissue growth factor: a novel player in tissue reorganization after brain injury?. Eur J Neurosci. 2000, 12 (1): 376-380. 10.1046/j.1460-9568.2000.00930.x.PubMedView Article
  17. Hallam TM, Floyd CL, Folkerts MM, Lee LL, Gong QZ, Lyeth BG, Muizelaar JP, Berman RF: Comparison of behavioral deficits and acute neuronal degeneration in rat lateral fluid percussion and weight-drop brain injury models. J Neurotrauma. 2004, 21 (5): 521-539. 10.1089/089771504774129865.PubMedView Article


© Liu et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.